Patent · US Expired

Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin

US6555116B1 · kind B1 · utility

2Cited by
3References
25Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 27, 1999
Grant dateApr 29, 2003
Priority date
Expiry dateJan 27, 2019

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10T436/182
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Thioredoxin, a small dithiol protein, is a specific reductant for allergenic proteins and particularly allergenic proteins present in pollen and animal and plant sources. All targeted proteins contain disulfide (S—S) bonds that are reduced to the sulfhydryl (SH) level by thioredoxin. The proteins are allergenically active and less digestible in the oxidized (S—S) state. When reduced (SH state), they lose their allergenicity and/or become more digestible. Thioredoxin achieved this reduction when activated (reduced) either by NADPH via NADP-thioredoxin reductase (physiological conditions) or by lipoic acid chemical reductant. Skin tests carried out with sensitized dogs showed that treatment of the pollens with reduced thioredoxin prior to injection eliminated or decreased the allergenicity of the pollen. Studies showed increased digestion of the pollen proteins by pepsin following reduction by thioredoxin. Pollen proteins that have been reduced by thioredoxin are effective and safe immunotherapeutic agents for decreasing or eliminating an animal's allergic reaction that would otherwise occur upon exposure to the non-reduced pollen protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.